Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.

CNS Oncol

Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, G61 1QH, Scotland.

Published: June 2022

Glioblastoma (GBM) accounts for over 50% of gliomas and carries the worst prognosis of all solid tumors. Owing to the limited local control afforded by surgery alone, efficacious adjuvant treatments such as radiotherapy (RT) and chemotherapy are fundamental in achieving durable disease control. The best clinical outcomes are achieved with tri-modality treatment consisting of surgery, RT and systemic therapy. While RT-chemotherapy combination regimens are well established in oncology, this approach was largely unsuccessful in GBM until the introduction of temozolomide. The success of this combination has stimulated the search for other candidate drugs for concomitant use with RT in GBM. This review seeks to collate the current evidence for these agents and synthesize possible future directions for the field.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134931PMC
http://dx.doi.org/10.2217/cns-2021-0015DOI Listing

Publication Analysis

Top Keywords

radiotherapy-drug combinations
4
combinations treatment
4
treatment glioblastoma
4
glioblastoma review
4
review glioblastoma
4
glioblastoma gbm
4
gbm accounts
4
accounts 50%
4
50% gliomas
4
gliomas carries
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!